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Abstract
New treatments for malaria are urgently needed due to the increasing problem of drug-resistance in malaria
parasites. The long-established use of quinine and the more recent introduction of artemisinin and its
derivatives as highly eﬀective antimalarials demonstrates that plant species are an important resource for
the discovery of new antimalarial agents. Furthermore, many plant species continue to be used in tradi-
tional medicines for the treatment of malaria and many people depend on such remedies as they cannot
aﬀord and/or do not have access to eﬀective antimalarial drugs. In this paper the potential of plant species
to yield new leads to antimalarial drugs will be illustrated with reference to cryptolepine, the main alkaloid
present in the species, Cryptolepis sanguinolenta. In addition to this approach, there is currently increasing
interest in the use and development of traditional herbal remedies for the treatment of malaria as these may
have the potential to provide aﬀordable antimalarial treatment for many who cannot aﬀord the drugs
needed to treat chloroquine-resistant Plasmodium falciparum infections. However, little is known with
respect to the eﬃcacy and safety of traditional antimalarials and clinical studies are urgently needed to
establish their value. Some of the issues pertinent to this area will be brieﬂy reviewed and it is hoped that
this will stimulate further discussion and research on this important topic.
Introduction
It is estimated that malaria is directly responsible
for the deaths of 1–2 million people each year
(Bradley, 1995), and in addition, the disease con-
tributes to an unknown number of other deaths as
a result of malaria-related anaemia. The majority
of malaria deaths are due to cerebral malaria and
other complications following infection with
P. falciparum that is transmitted by female mos-
quitoes of the genus Anopheles. Most of the deaths
occur in Africa and in children under the age of
5 years (Winstanley, 2000). Undoubtedly, the sit-
uation has become steadily worse in the last
30 years, and a major factor responsible has been
the increasing prevalence of P. falciparum resistant
to chloroquine and to other antimalarial agents.
Studies in a number of African countries have
shown that the emergence of chloroquine-resistant
malaria parasites is associated with a two-fold
increase in malaria deaths but in one study in
Mlomp, Senegal it was shown that malaria mor-
tality in children under the age of 4 years increased
11-fold within 6 years of the emergence of
chloroquine-resistance (Trape et al., 2002).
In 1972, Chinese scientists isolated artemisinin
(Figure 1), an unusual endoperoxide sesquiterpene
lactone as the active principle from Artemisia
annua (Asteraceae) and it was quickly shown to be
a rapidly acting antimalarial drug eﬀective against
chloroquine (and other drug) resistant parasites
and as good as quinine (but less toxic) for the
treatment of cerebral malaria (Klayman, 1985). As
artemisinin is a non-polar compound, derivatives
including ethers (artemether, arteether) and esters
(sodium artesunate, sodium artelinate) were
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prepared to improve its formulation characteristics
and these are now increasingly used as an alter-
native to quinine (Wilairatana and Looareesuwan,
2002). The development of the artemisinin deriv-
atives has been a major advance in the chemo-
therapy of malaria. However, although these
agents are highly eﬀective, of low toxicity and have
even been shown to reduce malaria transmission
on account of their eﬀects on the gametocyte
(mosquito infective) stages of the parasite (Price
et al., 1996), the artemisinin derivatives do have
limitations.
The ﬁrst of these is the problem of recrudes-
cence where drug treatment initially appears to
clear all the parasites from the blood but, after a
few weeks parasites re-appear and the disease
recurs. Recrudescence is not due to drug resistance
or re-infection of the patient but occurs because
the drug has failed to kill all of the parasites and
those that survive continue to multiply, so that
after a few weeks the patient again experiences
malaria symptoms. This problem may be related
to the relatively short half lives of the commonly
used artemisinin derivatives and the insensitivity of
the early blood stage forms of the malaria parasite
to these drugs (Wright and Warhurst, 2002). To
overcome this problem longer courses of treatment
may be given or, preferably, as recommended by
the World Health Organisation, treatment with an
artemisinin derivative should be followed by a
dose of a second antimalarial to clear any remain-
ing parasites (Wilairatana and Looareesuwan,
2002). The second and perhaps more important
limitation is that compared to chloroquine, the
artemisinin derivatives are expensive and out of
the reach of many of those who suﬀer from ma-
laria especially if treatment has to be followed by a
second drug. The rise in malaria mortality and
morbidity as a result of chloroquine-resistant
malaria parasites coupled with poverty in Africa
means that there continues to be an increasingly
urgent need for eﬀective and aﬀordable antima-
larial therapies. Even if the artemisinin derivatives
could be made available to all those that need
them, the possibility of the future development of
malaria parasites resistant to these drugs must be
borne in mind.
Plant-derived antimalarials have made and
continue to make an immense contribution to
malaria chemotherapy and it is the purpose of this
review to consider the future potential of plants to
provide new antimalarial treatments. Two
diﬀerent approaches to the development of new
medicines for malaria will be considered: In the
ﬁrst an example of the potential of plants to yield
novel compounds that can be investigated as leads
to new drugs will be discussed, while the second
will explore some of the issues with respect to the
use of traditional herbal medicines for the treat-
ment of malaria.
Leads to new antimalarial drugs
The importance of quinine (and of synthetic drugs
derived from quinine such as chloroquine and
meﬂoquine), and more recently of artemisinin and
its semi-synthetic derivatives as plant-derived
antimalarials (Figure 1), has encouraged the
continuing search for new natural product-derived
antimalarials. Many plant extracts, especially
those from species with a reputation for use in
traditional medicines have been evaluated in the
laboratory for in vitro antiplasmodial activities
and some have also been tested in vivo, usually in
mice infected with P. berghei or P. yoelii (for
reviews see del Rayo Camacho Corona et al., 2000;
Schwikkard and van Heerden, 2002). In some
cases, the constituent(s) responsible for their
activities have been isolated and their structures
elucidated but relatively few have been studied
Figure 1. Structures of some antimalarial natural products.
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further to assess their potential as lead compounds
for the development of new antimalarial drugs.
One example of a plant compound that is cur-
rently of interest as a potential lead compound
is the alkaloid cryptolepine, a constituent of
C. sanguinolenta.
Cryptolepine – a lead to new antimalarial agents?
A decoction of the roots of the climbing shrub
C. sanguinolenta is used in West Africa for the
treatment of malaria (Boye and Ampofo, 1983).
The plant contains a number of indoloquinoline
alkaloids of which cryptolepine (Figure 1), is the
major constituent and also the compound pos-
sessing the most potent antiplasmodial activity
(Cimanga et al., 1997). Cryptolepine is present in
relatively large amounts in the roots of C. sangu-
inolenta (>1% of the dried roots), and it has potent
in vitro activities against both chloroquine-sensi-
tive and chloroquine-resistant P. falciparum
(Wright et al., 2001). The synthesis of cryptolepine
is straightforward and was in fact accomplished
before the alkaloid was isolated from natural
sources (Fichter and Boehringer, 1906), thus giv-
ing potential for the preparation of cryptolepine
analogues for assessment as antimalarials. These
features would suggest that cryptolepine may be a
viable lead compound, but this alkaloid unfortu-
nately has other less promising attributes. When
tested in several cancer cell lines cryptolepine was
found to be moderately toxic and subsequent
investigations showed that this is due to the DNA
intercalating and topoisomerase II inhibiting
properties of the drug (Bonjean et al., 1998). In
addition, cryptolepine has been shown to inhibit
DNA synthesis (Bonjean et al., 1998) and is toxic
to mice when given by I.P. injection (Wright et al.,
2001). Although oral doses of cryptolepine did not
appear to be toxic to mice infected with P. berghei,
treatment with 50 mg kg)1 day)1 failed to cure the
malaria infection although parasitaemia was
reduced by 80% compared to control animals
(Wright et al., 1996). These results indicated that
cryptolepine is toxic and suggest that its oral bio-
availability may be poor, properties that might
preclude its consideration as a lead antimalarial
agent. However, further experiments showed that,
like chloroquine, cryptolepine inhibited the for-
mation of b-haematin in a cell-free system (Wright
et al., 2001). Quinoline antimalarials such as
chloroquine are believed to act by binding to
haem, the residue left behind following the diges-
tion of haemoglobin by malaria parasites infecting
red blood cells (Egan et al., 1994). Haem is toxic to
the parasite but it is detoxiﬁed by conversion into
malaria pigment (also known as haemozoin), and
this has been shown to be identical to b-haematin
(Bohle et al., 1997). This ﬁnding raised the possi-
bility that the antimalarial mode of action of cry-
ptolepine may be diﬀerent from its cytotoxic
mechanism of action, thus it was decided to pre-
pare analogues of cryptolepine in an attempt to
retain or enhance the antiplasmodial activity and
reduce cytotoxicity. It was hoped that by substi-
tuting atoms or groups into the molecule that the
intercalating ability of the molecule would be
attenuated. Several routes are available for the
synthesis of cryptolepine analogues but the one
mainly employed in the author’s laboratory was
that based on the synthesis of quindoline (Holt
and Petrow, 1947) in which isatin is condensed
with O, N-diacetylindoxyl in the presence of alkali
in oxygen-free conditions and the resulting
quindoline-11-carboxylic acid is decarboxylated by
heating in diphenylether to yield quindoline
(Scheme 1). Cryptolepine is then prepared by
methylating quindoline with iodomethane
using sulpholane as a solvent. By using substituted
O, N-diacetylindoxyl and/or isatin derivatives as
starting materials a wide range of cryptolepine
analogues may be easily prepared although some
Scheme 1a. Synthesis of cryptolepine.
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strongly electron withdrawing substituents such as
nitro groups inhibit the ﬁrst step in the synthesis.
As a result of testing a series of cryptolepine
analogues against P. falciparum (multi-drug resis-
tant strain K1) in vitro it was found that both the
2- and 7-bromocryptolepine derivatives were two-
fold more potent than the parent and this
prompted the synthesis of 2,7-dibromocryptole-
pine. The latter was found to be nearly 10-fold
more active against P. falciparum than cryptole-
pine (IC50 values 0.049 and 0.44, respectively).
Furthermore, tests on a series of analogues against
chloroquine-sensitive (strain HB3) and chloro-
quine-resistant (strain K1) P. falciparum showed
that there was no cross-resistance with chloro-
quine (Wright et al., 2001). A number of com-
pounds were then tested in mice infected with
P. berghei using Peters’ 4-day suppressive test
(Peters et al., 1975). The 2-bromo- and 7-bromo-
analogues (at doses of 25 and 20 mg Kg day)1,
respectively) suppressed parasitaemia in the mice
by 6 and 42%, respectively, compared to untreated
infected controls, but 2,7-dibromocryptolepine (at
a dose of 12.5 mg Kg day)1) gave 89% suppres-
sion, thus correlating with the enhanced activity
seen in vitro. Importantly, no toxic eﬀects were
seen in the mice but cryptolepine itself was toxic
(Wright et al., 2001). Interestingly, not all dihalo-
genated analogues exhibited increased activities
compared to the monosubstituted compounds;
for example, 11-chlorocryptolepine was 2-fold
more potent than cryptolepine against P. falcipa-
rum in vitro but 2-bromo, 11-chlorocryptolepine
was 10-fold less active than the parent. Although,
the 2-bromo-, 7-bromo-, and 2,7-dibromo-ana-
logues were not toxic to the mice, they were not
less cytotoxic than cryptolepine but they did ap-
pear to be less able to intercalate into DNA as
shown by measurements of their eﬀects on the
melting point of calf-thymus DNA. Their DTm
values were 4, 4 and 3 C, respectively, while the
DTm value for cryptolepine was 9 C (Wright
et al., 2001). The enhancement of both in vitro and
in vivo antimalarial activities by 7-bromo- substi-
tution has been conﬁrmed by the synthesis of
several analogues including 2-chloro, 7-bromo- and
2-bromo, 7-nitrocryptolepine and these compounds
showpotent in vitro antiplasmodial activities as well
as >90% suppression of parasitaemia in the mouse
4-day suppressive test at doses of 25 mg Kg)1 day)1
(Onyeibor et al., 2005). Furthermore, the survival
times of the mice compared to untreated controls
were increased. Taken together, these data indicate
that cryptolepine analogues are worthy of further
study as lead antimalarial compounds although
there are signiﬁcant hurdles to be overcome, par-
ticularly the need for compounds thatwill produce a
cure in mice infected with malaria and which can be
shown to be orally active. The synthesis of new
analogues and studies investigating the mode of
action of cryptolepine and its analogues are
continuing.
Traditional antimalarials
Since, as mentioned above, antimalarial drugs
(other than chloroquine), are unavailable or
unaﬀordable to many who live in malarious
areas, the use of traditional medicines for ma-
laria treatment is an attractive and often the
only option. The plants required are locally
available (although supplies may become more
diﬃcult as time goes on due to overcollection,
deforestation and development), and traditional
medicines are more aﬀordable as well as being
culturally acceptable. They are widely used for
the treatment of malaria and fever but little is
known concerning their clinical eﬃcacy and
safety since few clinical studies have been carried
out. Indeed, given the increasing mortality due
to malaria it may be pertinent to question the
eﬀectiveness of traditional antimalarials: if these
remedies are eﬀective why are there so many
deaths from malaria? Clinical trials are urgently
needed to answer this question. With a view to
address the above, the Research initiative on
traditional antimalarials (RITAM) has been
established by the organisation Global Initiative
for Traditional Systems of Health (GIFTS of
Health) initiated by Dr G. Bodeker, Oxford,
UK. RITAM is a global network of people who
are interested in validating local herbal medicines
used for the prevention and/or the treatment of
malaria and also local methods for insect repel-
lance and vector control. It is hoped that these
might provide eﬀective treatments for those for
whom manufactured drugs are not available as
well as eﬀective and aﬀordable methods for
vector control. RITAM members have recently
compiled a book on traditional antimalarials
including a review of clinical trials that have
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been carried out to date (Willcox et al., 2004).
For further information about RITAM readers
are welcome to contact Dr Merlin Willcox, e-mail:
merlinwillcox@doctors.net.uk.
Clinical trials with traditional antimalarials
The design and execution of clinical trials for
traditional antimalarials presents a considerable
challenge and a few of the reasons why this is the
case will be outlined below. Firstly, malaria is a
complex disease and a thorough understanding is
essential in order to design studies that will pro-
duce meaningful data. Perhaps the most impor-
tant question with respect to a traditional
antimalarial is ‘Will this medicine prevent, (or at
least reduce), the risk of severe disease and death
from malaria?’. This apparently straightforward
question is particularly diﬃcult to answer given
that deaths from malaria may occur in less than
one in 200 untreated patients (Trape et al., 2002).
Thus, large numbers of patients would be needed
to show a signiﬁcant reduction in death or severe
disease. The situation is further complicated by
the immune status of the patient. Most of the
deaths due to malaria occur in children under the
age of 5 years who have little or no immunity to
the disease. Children in Africa suﬀer repeated
episodes of malaria, and if they survive gradually
develop partial immunity to the disease so that
children over 5 years and adults are much less
likely to die from malaria or suﬀer severe disease.
However, during their ﬁrst pregnancy especially,
women and their unborn children are at great
risk from malaria because the immune response
is suppressed in pregnancy and parasitised red
cells accumulate in the placenta (Warrell and
Gilles, 2002). Also, non-immune older children
and adults that move from non-malarious to
malarious areas are at risk of severe disease/
death. Even if it is demonstrated that a tradi-
tional medicine is eﬀective in older, partially-im-
mune patients, it may not necessarily be eﬀective
in young children, (or others) with little or no
immunity to the eﬀects of malaria infection. The
immune status of the patient must therefore be
considered when carrying out studies with anti-
malarials as partially-immune patients may well
recover from the disease without the need for
drug therapy and properly matched untreated
controls would be needed to show any beneﬁcial
eﬀects of the medicine under test. In addition,
there are many other practical and ethical diﬃ-
culties that need to be considered.
As noted above, the extracts of many plant
species used in traditional antimalarials have been
evaluated in the laboratory for their in vitro anti-
plasmodial activities and some have been
tested for in vivo antimalarial activities; for reviews
see (del Rayo Camacho Corona et al., 2000;
Schwikkard and van Heerden, 2002). Often the
results show only modest activity against the par-
asites in vitro or against malaria in mice. This
would suggest that the species are likely to have
only a limited eﬀect in man and that cure of the
disease is unlikely. However, this may not neces-
sarily mean that medicines made from these spe-
cies are of no value. Partially eﬀective treatments
might be beneﬁcial in that the course of the disease
is shortened perhaps reducing anaemia and low-
ering the risk of death or serious illness from other
anaemia-related diseases. Other possible beneﬁts
could be the alleviation of symptoms such as pain
and fever and immunomodulation leading to in-
creased immunity. For example, species of Alsto-
nia are widely used traditionally for the treatment
of malaria but there is little convincing evidence
that these species have antiplasmodial or antima-
larial properties (Wright et al., 1993), although the
alkaloids from Alstonia scholaris have been re-
ported to have pronounced febrifugal eﬀects in
fowls with malaria (Mukerji, 1946). Strychnos
myrtoides is a plant used in Madagascar as an
adjuvant with chloroquine for the treatment of
malaria. Although the major alkaloid constituents
are devoid of activity against malaria parasites,
they have been shown to potentiate the action of
chloroquine against chloroquine-resistant para-
sites (Rasoanaivo et al., 1994). The antimalarial
action of the Chinese herb Dichroa febrifuga is
thought to involve the immune response as it
stimulates activated macrophages to produce nitric
oxide (Murata, et al., 1998).
Interestingly, in 1938 D.B. Wilson suggested
that when treating malaria, only minimal therapy
should be used, suﬃcient to prevent death but
insuﬃcient to clear all the parasites from the blood
so that the development of immunity is not
impaired (Trape et al., 2002). This suggestion has
resulted in much debate over the years and in the
context of traditional antimalarials raises the
possibility that partially eﬀective remedies might
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be better in the long term than curative treatment
since they might allow better development of
immunity. However, it must be emphasised that
the above is speculative and further clinical studies
are needed in order to resolve this and other issues
related to the use of traditional antimalarials.
Only a few clinical studies with traditional
antimalarials have been carried out and these have
recently been reviewed (Willcox et al., 2004).
Currently, there is considerable interest in using
locally grown A. annua (the source of artemisinin)
for the treatment of malaria but to date only two
clinical studies have been reported. These will be
brieﬂy discussed below as they illustrate some of
the diﬃculties and limitations typical of many of
the trials carried out with herbal antimalarials. In
1992 in China, 144 malaria patients were treated
with tablets containing an ethanolic extract of
A. annua or with capsules in which the extract was
formulated in oil (Yao-De et al., 1992, reviewed in
Yu and Zhong, 2002). The treatments were found
to be eﬀective in reducing parasitaemia and fever at
doses equivalent to 80.8 g raw herb for the tablets
and 73.6 g for the capsules, given over 3 days.
More recently, a herbal tea prepared from A. annua
was evaluated in malaria patients in the
Democratic Republic of Congo with the result that
clearance of parasitaemia and a reduction of
symptoms was reported in 92% of 48 patients after
4 days treatment (Mueller et al., 2000). In both of
the above studies, patients were over the age of
10 years and therefore they were likely to be par-
tially-immune to malaria. In the Chinese study,
follow up of patients for 30 days showed that
recrudescence was common (about 30% although
this was reduced to 8% in patients treated with the
capsule formulation for 6 days), but there was no
follow up in the other study. The amount of arte-
misinin present in the herbal tea used in the Con-
golese study was determined by analysis and this
was found to be much less than the usual clinically
used dose. However, it is possible that the smaller
dose present in the herbal tea may be adequate
especially if the subjects had partial immunity to
malaria, although a diﬀerence in the eﬃcacy of
artemisinin between non-immune and partially-
immune malaria patients has not been shown. It is
also possible that other compounds in the tea such
as ﬂavonoids acted synergistically with the arte-
misinin or enhanced its bioavailability. Experi-
mental evidence from in vitro studies suggests that
some ﬂavonoids may enhance the action of
artemisinin against P. falciparum (Elford et al.,
1987). If however, parasites are exposed to sub-
therapeutic doses of artemisinin there is the possi-
bility that the development of parasites resistant to
artemisinin may be encouraged. To date there have
been no clinical reports of artemisinin resistance
but resistant parasites have been produced in the
laboratory (Chawira et al., 1986). Although it has
been argued that the development of malaria
parasites resistant to artemisinin is unlikely be-
cause of the rapid action and short half-life of the
drug, the ability of microorganisms to develop
resistance should not be underestimated.
It is clear from the above that the eﬀectiveness
of A. annua used as a herbal tea or in the form of a
crude extract to treat malaria in non-immune pa-
tients has not yet been demonstrated and it may be
unwise to promote the use of such preparations at
least in young children until further studies have
been carried out.
Conclusion
The investigation of plants used in traditional
medicines for the treatment of malaria may well
lead to the development of new antimalarial drugs.
Cryptolepine is a promising lead compound and
several analogues have a potent suppressive eﬀect
on parasitaemia in mice infected with P. berghei
with no apparent toxicity to the mice. However,
analogues that are able to cure malaria in mice are
yet to be found. As an alternative approach to drug
development, the further investigation of tradi-
tional antimalarials is an attractive option, but
showing that these remedies are eﬀective especially
in preventing severe disease or death from malaria
in young children presents a considerable chal-
lenge. The bark of a South American Cinchona tree
provided quinine and a herb from China furnished
artemisinin, but bearing in mind that malaria is
primarily an African problem, it is to be hoped that
in the future we can look forward to antimalarials
from Africa for Africa.
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